Literature DB >> 21135991

Increased intracellular iron and mineralization of cultured hFOB 1.19 cells following hepcidin activation through ferroportin-1.

Peng Zhang1, You-jia Xu, Dong-Yang Zhao, Yong Ma, Li Xiao, Yu-Shuang Feng, Ben-Cai Du, Zhong-Ming Qian, Kai Li.   

Abstract

OBJECTIVE: To address whether hepcidin functions in bone metabolism.
METHODS: This study was carried out in the Laboratory of Radiation Medicine and Public Health of Soochow University, and the Laboratory of the Second Affiliated Hospital of Soochow University, Suzhou, China, from September 2009 to July 2010. The positive expression of ferroportin-1 (Fpn-1) was detected by reverse transcriptase-polymerase chain reaction. After the treatment with distilled water (control group) and hepcidin (25noml/L, 50noml/L, 100noml/L), the fluorescence intensity related to intracellular iron concentration of a human fetal osteoblast cell line (hFOB 1.19) was measured by a confocal laser scanning microscope. A 3-(4,5- dimethylthiazol-2-yl) -2-5-diphenyltetrazolium bromide assay, and Von Kossa staining was performed to evaluate cell proliferation and mineralization in cultured hFOB 1.19 cells.
RESULTS: This study revealed a high level expression of Fpn-1 in hFOB 1.19. On the basis of which, it was found that 25noml/L, 50noml/L, 100noml/L hepcidin could promote the fluorescence intensity related to intracellular iron concentration and mineralization in hFOB 1.19 in a dose-dependent manner (p<0.05), but hepcidin had no effect on FOB 1.19 proliferation (p>0.05).
CONCLUSION: The hepcidin-ferroportin signal pathway may function in the osteoblast cell line of hFOB 1.19 cells. It is also suggested that cross-talk between iron and calcium homeostasis may play a role in bone metabolism in responding to hepcidin activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135991

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  5 in total

1.  Reducing iron accumulation: A potential approach for the prevention and treatment of postmenopausal osteoporosis.

Authors:  Bin Chen; Guang-Fei Li; Ying Shen; X I Huang; You-Jia Xu
Journal:  Exp Ther Med       Date:  2015-05-08       Impact factor: 2.447

Review 2.  Iron homeostasis in osteoporosis and its clinical implications.

Authors:  G F Li; Y Z Pan; P Sirois; K Li; Y J Xu
Journal:  Osteoporos Int       Date:  2012-04-14       Impact factor: 4.507

3.  Effects of mouse hepcidin 1 treatment on osteoclast differentiation and intracellular iron concentration.

Authors:  Guo-yang Zhao; Dong-hua Di; Bo Wang; Xi Huang; You-jia Xu
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

4.  Hepcidin promotes osteogenic differentiation through the bone morphogenetic protein 2/small mothers against decapentaplegic and mitogen-activated protein kinase/P38 signaling pathways in mesenchymal stem cells.

Authors:  Huading Lu; Liyi Lian; Dehai Shi; Huiqing Zhao; Yuhu Dai
Journal:  Mol Med Rep       Date:  2014-10-24       Impact factor: 2.952

5.  Pentosan polysulfate regulates hepcidin 1-facilitated formation and function of osteoclast derived from canine bone marrow.

Authors:  Suranji Wijekoon; Takafumi Sunaga; Yanlin Wang; Carol Mwale; Sangho Kim; Masahiro Okumura
Journal:  PLoS One       Date:  2022-03-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.